

Global Non-Insulin Hypoglycemic Drug Market Growth 2022-2028

<https://marketpublishers.com/r/G765EC5711ABEN.html>

Date: November 2022

Pages: 114

Price: US\$ 3,660.00 (Single User License)

ID: G765EC5711ABEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global market for Non-Insulin Hypoglycemic Drug is estimated to increase from US\$ million in 2021 to reach US\$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Non-Insulin Hypoglycemic Drug market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Non-Insulin Hypoglycemic Drug market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Non-Insulin Hypoglycemic Drug market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Non-Insulin Hypoglycemic Drug market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Non-Insulin Hypoglycemic Drug players cover GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics and Servier, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage

This latest report provides a deep insight into the global Non-Insulin Hypoglycemic Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Non-Insulin Hypoglycemic Drug market, with both quantitative and qualitative data, to help readers understand how the Non-Insulin Hypoglycemic Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:

The study segments the Non-Insulin Hypoglycemic Drug market and forecasts the market size by Type (Sulfonylureas, Meglitinides and Biguanides), by Application (Hospital Pharmacies and Retail Pharmacies.), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type

Sulfonylureas

Meglitinides

Biguanides

Thiazolidinediones

Alpha Glucosidase Inhibitors

Others

Segmentation by application

Hospital Pharmacies

Retail Pharmacies

Segmentation by region

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

Major companies covered

GSK

Eli Lilly

Sumitomo Dainippon Pharma

Intarcia Therapeutics

Servier

Pfizer

Merck

Dong-A Pharmaceutical

Luye Pharma Group

Eurofarma

Geropharm

Alkem Labs

Jiangsu Hansoh Pharmaceutical

Novo Nordisk

Emisphere

Uni-Bio Science Group

Takeda

3SBio

Jiangsu Hengrui Medicine

Chapter Introduction

Chapter 1: Scope of Non-Insulin Hypoglycemic Drug, Research Methodology, etc.

Chapter 2: Executive Summary, global Non-Insulin Hypoglycemic Drug market size (sales and revenue) and CAGR, Non-Insulin Hypoglycemic Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.

Chapter 3: Non-Insulin Hypoglycemic Drug sales, revenue, average price, global market share, and industry ranking by company, 2017-2022

Chapter 4: Global Non-Insulin Hypoglycemic Drug sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.

Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.

Chapter 9: Analysis of the current market trends, market forecast, opportunities and

economic trends that are affecting the future marketplace

Chapter 10: Manufacturing cost structure analysis

Chapter 11: Sales channel, distributors, and customers

Chapter 12: Global Non-Insulin Hypoglycemic Drug market size forecast by region, by country, by type, and application.

Chapter 13: Comprehensive company profiles of the leading players, including GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical and Luye Pharma Group, etc.

Chapter 14: Research Findings and Conclusion

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Non-Insulin Hypoglycemic Drug Annual Sales 2017-2028
 - 2.1.2 World Current & Future Analysis for Non-Insulin Hypoglycemic Drug by Geographic Region, 2017, 2022 & 2028
 - 2.1.3 World Current & Future Analysis for Non-Insulin Hypoglycemic Drug by Country/Region, 2017, 2022 & 2028
- 2.2 Non-Insulin Hypoglycemic Drug Segment by Type
 - 2.2.1 Sulfonylureas
 - 2.2.2 Meglitinides
 - 2.2.3 Biguanides
 - 2.2.4 Thiazolidinediones
 - 2.2.5 Alpha Glucosidase Inhibitors
 - 2.2.6 Others
- 2.3 Non-Insulin Hypoglycemic Drug Sales by Type
 - 2.3.1 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
 - 2.3.2 Global Non-Insulin Hypoglycemic Drug Revenue and Market Share by Type (2017-2022)
 - 2.3.3 Global Non-Insulin Hypoglycemic Drug Sale Price by Type (2017-2022)
- 2.4 Non-Insulin Hypoglycemic Drug Segment by Application
 - 2.4.1 Hospital Pharmacies
 - 2.4.2 Retail Pharmacies
- 2.5 Non-Insulin Hypoglycemic Drug Sales by Application
 - 2.5.1 Global Non-Insulin Hypoglycemic Drug Sale Market Share by Application (2017-2022)
 - 2.5.2 Global Non-Insulin Hypoglycemic Drug Revenue and Market Share by

Application (2017-2022)

2.5.3 Global Non-Insulin Hypoglycemic Drug Sale Price by Application (2017-2022)

3 GLOBAL NON-INSULIN HYPOGLYCEMIC DRUG BY COMPANY

3.1 Global Non-Insulin Hypoglycemic Drug Breakdown Data by Company

3.1.1 Global Non-Insulin Hypoglycemic Drug Annual Sales by Company (2020-2022)

3.1.2 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Company (2020-2022)

3.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Non-Insulin Hypoglycemic Drug Revenue by Company (2020-2022)

3.2.2 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company (2020-2022)

3.3 Global Non-Insulin Hypoglycemic Drug Sale Price by Company

3.4 Key Manufacturers Non-Insulin Hypoglycemic Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Non-Insulin Hypoglycemic Drug Product Location Distribution

3.4.2 Players Non-Insulin Hypoglycemic Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR NON-INSULIN HYPOGLYCEMIC DRUG BY GEOGRAPHIC REGION

4.1 World Historic Non-Insulin Hypoglycemic Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Non-Insulin Hypoglycemic Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue by Geographic Region

4.2 World Historic Non-Insulin Hypoglycemic Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Non-Insulin Hypoglycemic Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue by Country/Region

4.3 Americas Non-Insulin Hypoglycemic Drug Sales Growth

4.4 APAC Non-Insulin Hypoglycemic Drug Sales Growth

4.5 Europe Non-Insulin Hypoglycemic Drug Sales Growth

4.6 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Growth

5 AMERICAS

5.1 Americas Non-Insulin Hypoglycemic Drug Sales by Country

5.1.1 Americas Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022)

5.1.2 Americas Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022)

5.2 Americas Non-Insulin Hypoglycemic Drug Sales by Type

5.3 Americas Non-Insulin Hypoglycemic Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Non-Insulin Hypoglycemic Drug Sales by Region

6.1.1 APAC Non-Insulin Hypoglycemic Drug Sales by Region (2017-2022)

6.1.2 APAC Non-Insulin Hypoglycemic Drug Revenue by Region (2017-2022)

6.2 APAC Non-Insulin Hypoglycemic Drug Sales by Type

6.3 APAC Non-Insulin Hypoglycemic Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Non-Insulin Hypoglycemic Drug by Country

7.1.1 Europe Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022)

7.1.2 Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022)

7.2 Europe Non-Insulin Hypoglycemic Drug Sales by Type

7.3 Europe Non-Insulin Hypoglycemic Drug Sales by Application

7.4 Germany

7.5 France

- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Non-Insulin Hypoglycemic Drug by Country
 - 8.1.1 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022)
 - 8.1.2 Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022)
- 8.2 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Type
- 8.3 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Non-Insulin Hypoglycemic Drug
- 10.3 Manufacturing Process Analysis of Non-Insulin Hypoglycemic Drug
- 10.4 Industry Chain Structure of Non-Insulin Hypoglycemic Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Non-Insulin Hypoglycemic Drug Distributors
- 11.3 Non-Insulin Hypoglycemic Drug Customer

12 WORLD FORECAST REVIEW FOR NON-INSULIN HYPOGLYCEMIC DRUG BY GEOGRAPHIC REGION

- 12.1 Global Non-Insulin Hypoglycemic Drug Market Size Forecast by Region
 - 12.1.1 Global Non-Insulin Hypoglycemic Drug Forecast by Region (2023-2028)
 - 12.1.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Non-Insulin Hypoglycemic Drug Forecast by Type
- 12.7 Global Non-Insulin Hypoglycemic Drug Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 GSK
 - 13.1.1 GSK Company Information
 - 13.1.2 GSK Non-Insulin Hypoglycemic Drug Product Offered
 - 13.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.1.4 GSK Main Business Overview
 - 13.1.5 GSK Latest Developments
- 13.2 Eli Lilly
 - 13.2.1 Eli Lilly Company Information
 - 13.2.2 Eli Lilly Non-Insulin Hypoglycemic Drug Product Offered
 - 13.2.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.2.4 Eli Lilly Main Business Overview
 - 13.2.5 Eli Lilly Latest Developments
- 13.3 Sumitomo Dainippon Pharma
 - 13.3.1 Sumitomo Dainippon Pharma Company Information
 - 13.3.2 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Offered
 - 13.3.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.3.4 Sumitomo Dainippon Pharma Main Business Overview
 - 13.3.5 Sumitomo Dainippon Pharma Latest Developments
- 13.4 Intarcia Therapeutics

- 13.4.1 Intarcia Therapeutics Company Information
- 13.4.2 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Offered
- 13.4.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.4.4 Intarcia Therapeutics Main Business Overview
- 13.4.5 Intarcia Therapeutics Latest Developments
- 13.5 Servier
 - 13.5.1 Servier Company Information
 - 13.5.2 Servier Non-Insulin Hypoglycemic Drug Product Offered
 - 13.5.3 Servier Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.5.4 Servier Main Business Overview
 - 13.5.5 Servier Latest Developments
- 13.6 Pfizer
 - 13.6.1 Pfizer Company Information
 - 13.6.2 Pfizer Non-Insulin Hypoglycemic Drug Product Offered
 - 13.6.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.6.4 Pfizer Main Business Overview
 - 13.6.5 Pfizer Latest Developments
- 13.7 Merck
 - 13.7.1 Merck Company Information
 - 13.7.2 Merck Non-Insulin Hypoglycemic Drug Product Offered
 - 13.7.3 Merck Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.7.4 Merck Main Business Overview
 - 13.7.5 Merck Latest Developments
- 13.8 Dong-A Pharmaceutical
 - 13.8.1 Dong-A Pharmaceutical Company Information
 - 13.8.2 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
 - 13.8.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.8.4 Dong-A Pharmaceutical Main Business Overview
 - 13.8.5 Dong-A Pharmaceutical Latest Developments
- 13.9 Luye Pharma Group
 - 13.9.1 Luye Pharma Group Company Information
 - 13.9.2 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Offered
 - 13.9.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)

- 13.9.4 Luye Pharma Group Main Business Overview
- 13.9.5 Luye Pharma Group Latest Developments
- 13.10 Eurofarma
 - 13.10.1 Eurofarma Company Information
 - 13.10.2 Eurofarma Non-Insulin Hypoglycemic Drug Product Offered
 - 13.10.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.10.4 Eurofarma Main Business Overview
 - 13.10.5 Eurofarma Latest Developments
- 13.11 Geropharm
 - 13.11.1 Geropharm Company Information
 - 13.11.2 Geropharm Non-Insulin Hypoglycemic Drug Product Offered
 - 13.11.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.11.4 Geropharm Main Business Overview
 - 13.11.5 Geropharm Latest Developments
- 13.12 Alkem Labs
 - 13.12.1 Alkem Labs Company Information
 - 13.12.2 Alkem Labs Non-Insulin Hypoglycemic Drug Product Offered
 - 13.12.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.12.4 Alkem Labs Main Business Overview
 - 13.12.5 Alkem Labs Latest Developments
- 13.13 Jiangsu Hansoh Pharmaceutical
 - 13.13.1 Jiangsu Hansoh Pharmaceutical Company Information
 - 13.13.2 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
 - 13.13.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.13.4 Jiangsu Hansoh Pharmaceutical Main Business Overview
 - 13.13.5 Jiangsu Hansoh Pharmaceutical Latest Developments
- 13.14 Novo Nordisk
 - 13.14.1 Novo Nordisk Company Information
 - 13.14.2 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Offered
 - 13.14.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.14.4 Novo Nordisk Main Business Overview
 - 13.14.5 Novo Nordisk Latest Developments
- 13.15 Emisphere

- 13.15.1 Emisphere Company Information
- 13.15.2 Emisphere Non-Insulin Hypoglycemic Drug Product Offered
- 13.15.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.15.4 Emisphere Main Business Overview
- 13.15.5 Emisphere Latest Developments
- 13.16 Uni-Bio Science Group
 - 13.16.1 Uni-Bio Science Group Company Information
 - 13.16.2 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Offered
 - 13.16.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.16.4 Uni-Bio Science Group Main Business Overview
 - 13.16.5 Uni-Bio Science Group Latest Developments
- 13.17 Takeda
 - 13.17.1 Takeda Company Information
 - 13.17.2 Takeda Non-Insulin Hypoglycemic Drug Product Offered
 - 13.17.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.17.4 Takeda Main Business Overview
 - 13.17.5 Takeda Latest Developments
- 13.18 3SBio
 - 13.18.1 3SBio Company Information
 - 13.18.2 3SBio Non-Insulin Hypoglycemic Drug Product Offered
 - 13.18.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.18.4 3SBio Main Business Overview
 - 13.18.5 3SBio Latest Developments
- 13.19 Jiangsu Hengrui Medicine
 - 13.19.1 Jiangsu Hengrui Medicine Company Information
 - 13.19.2 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Offered
 - 13.19.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.19.4 Jiangsu Hengrui Medicine Main Business Overview
 - 13.19.5 Jiangsu Hengrui Medicine Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Non-Insulin Hypoglycemic Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)

Table 2. Non-Insulin Hypoglycemic Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)

Table 3. Major Players of Sulfonylureas

Table 4. Major Players of Meglitinides

Table 5. Major Players of Biguanides

Table 6. Major Players of Thiazolidinediones

Table 7. Major Players of Alpha Glucosidase Inhibitors

Table 8. Major Players of Others

Table 9. Global Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)

Table 10. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)

Table 11. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2017-2022) & (\$ million)

Table 12. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2017-2022)

Table 13. Global Non-Insulin Hypoglycemic Drug Sale Price by Type (2017-2022) & (US\$/Unit)

Table 14. Global Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)

Table 15. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)

Table 16. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2017-2022)

Table 17. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2017-2022)

Table 18. Global Non-Insulin Hypoglycemic Drug Sale Price by Application (2017-2022) & (US\$/Unit)

Table 19. Global Non-Insulin Hypoglycemic Drug Sales by Company (2020-2022) & (K Units)

Table 20. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Company (2020-2022)

Table 21. Global Non-Insulin Hypoglycemic Drug Revenue by Company (2020-2022) (\$ Millions)

Table 22. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company

(2020-2022)

Table 23. Global Non-Insulin Hypoglycemic Drug Sale Price by Company (2020-2022) & (US\$/Unit)

Table 24. Key Manufacturers Non-Insulin Hypoglycemic Drug Producing Area Distribution and Sales Area

Table 25. Players Non-Insulin Hypoglycemic Drug Products Offered

Table 26. Non-Insulin Hypoglycemic Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Non-Insulin Hypoglycemic Drug Sales by Geographic Region (2017-2022) & (K Units)

Table 30. Global Non-Insulin Hypoglycemic Drug Sales Market Share Geographic Region (2017-2022)

Table 31. Global Non-Insulin Hypoglycemic Drug Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 32. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Geographic Region (2017-2022)

Table 33. Global Non-Insulin Hypoglycemic Drug Sales by Country/Region (2017-2022) & (K Units)

Table 34. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Country/Region (2017-2022)

Table 35. Global Non-Insulin Hypoglycemic Drug Revenue by Country/Region (2017-2022) & (\$ millions)

Table 36. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Country/Region (2017-2022)

Table 37. Americas Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022) & (K Units)

Table 38. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2017-2022)

Table 39. Americas Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022) & (\$ Millions)

Table 40. Americas Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2017-2022)

Table 41. Americas Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)

Table 42. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)

Table 43. Americas Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) &

(K Units)

Table 44. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)

Table 45. APAC Non-Insulin Hypoglycemic Drug Sales by Region (2017-2022) & (K Units)

Table 46. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2017-2022)

Table 47. APAC Non-Insulin Hypoglycemic Drug Revenue by Region (2017-2022) & (\$ Millions)

Table 48. APAC Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2017-2022)

Table 49. APAC Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)

Table 50. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)

Table 51. APAC Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)

Table 52. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)

Table 53. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022) & (K Units)

Table 54. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2017-2022)

Table 55. Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022) & (\$ Millions)

Table 56. Europe Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2017-2022)

Table 57. Europe Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)

Table 58. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)

Table 59. Europe Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)

Table 60. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)

Table 61. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022) & (K Units)

Table 62. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2017-2022)

Table 63. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue by Country

(2017-2022) & (\$ Millions)

Table 64. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2017-2022)

Table 65. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)

Table 66. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)

Table 67. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)

Table 68. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)

Table 69. Key Market Drivers & Growth Opportunities of Non-Insulin Hypoglycemic Drug

Table 70. Key Market Challenges & Risks of Non-Insulin Hypoglycemic Drug

Table 71. Key Industry Trends of Non-Insulin Hypoglycemic Drug

Table 72. Non-Insulin Hypoglycemic Drug Raw Material

Table 73. Key Suppliers of Raw Materials

Table 74. Non-Insulin Hypoglycemic Drug Distributors List

Table 75. Non-Insulin Hypoglycemic Drug Customer List

Table 76. Global Non-Insulin Hypoglycemic Drug Sales Forecast by Region (2023-2028) & (K Units)

Table 77. Global Non-Insulin Hypoglycemic Drug Sales Market Forecast by Region

Table 78. Global Non-Insulin Hypoglycemic Drug Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 79. Global Non-Insulin Hypoglycemic Drug Revenue Market Share Forecast by Region (2023-2028)

Table 80. Americas Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 81. Americas Non-Insulin Hypoglycemic Drug Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 82. APAC Non-Insulin Hypoglycemic Drug Sales Forecast by Region (2023-2028) & (K Units)

Table 83. APAC Non-Insulin Hypoglycemic Drug Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 84. Europe Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 85. Europe Non-Insulin Hypoglycemic Drug Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 86. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Forecast by

Country (2023-2028) & (K Units)

Table 87. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 88. Global Non-Insulin Hypoglycemic Drug Sales Forecast by Type (2023-2028) & (K Units)

Table 89. Global Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Type (2023-2028)

Table 90. Global Non-Insulin Hypoglycemic Drug Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 91. Global Non-Insulin Hypoglycemic Drug Revenue Market Share Forecast by Type (2023-2028)

Table 92. Global Non-Insulin Hypoglycemic Drug Sales Forecast by Application (2023-2028) & (K Units)

Table 93. Global Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Application (2023-2028)

Table 94. Global Non-Insulin Hypoglycemic Drug Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 95. Global Non-Insulin Hypoglycemic Drug Revenue Market Share Forecast by Application (2023-2028)

Table 96. GSK Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors

Table 97. GSK Non-Insulin Hypoglycemic Drug Product Offered

Table 98. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 99. GSK Main Business

Table 100. GSK Latest Developments

Table 101. Eli Lilly Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors

Table 102. Eli Lilly Non-Insulin Hypoglycemic Drug Product Offered

Table 103. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 104. Eli Lilly Main Business

Table 105. Eli Lilly Latest Developments

Table 106. Sumitomo Dainippon Pharma Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors

Table 107. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Offered

Table 108. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

- Table 109. Sumitomo Dainippon Pharma Main Business
- Table 110. Sumitomo Dainippon Pharma Latest Developments
- Table 111. Intarcia Therapeutics Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 112. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Offered
- Table 113. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 114. Intarcia Therapeutics Main Business
- Table 115. Intarcia Therapeutics Latest Developments
- Table 116. Servier Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 117. Servier Non-Insulin Hypoglycemic Drug Product Offered
- Table 118. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 119. Servier Main Business
- Table 120. Servier Latest Developments
- Table 121. Pfizer Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 122. Pfizer Non-Insulin Hypoglycemic Drug Product Offered
- Table 123. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 124. Pfizer Main Business
- Table 125. Pfizer Latest Developments
- Table 126. Merck Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 127. Merck Non-Insulin Hypoglycemic Drug Product Offered
- Table 128. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 129. Merck Main Business
- Table 130. Merck Latest Developments
- Table 131. Dong-A Pharmaceutical Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 132. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
- Table 133. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 134. Dong-A Pharmaceutical Main Business
- Table 135. Dong-A Pharmaceutical Latest Developments
- Table 136. Luye Pharma Group Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors

Table 137. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Offered

Table 138. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 139. Luye Pharma Group Main Business

Table 140. Luye Pharma Group Latest Developments

Table 141. Eurofarma Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors

Table 142. Eurofarma Non-Insulin Hypoglycemic Drug Product Offered

Table 143. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 144. Eurofarma Main Business

Table 145. Eurofarma Latest Developments

Table 146. Geropharm Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors

Table 147. Geropharm Non-Insulin Hypoglycemic Drug Product Offered

Table 148. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 149. Geropharm Main Business

Table 150. Geropharm Latest Developments

Table 151. Alkem Labs Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors

Table 152. Alkem Labs Non-Insulin Hypoglycemic Drug Product Offered

Table 153. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 154. Alkem Labs Main Business

Table 155. Alkem Labs Latest Developments

Table 156. Jiangsu Hansoh Pharmaceutical Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors

Table 157. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered

Table 158. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 159. Jiangsu Hansoh Pharmaceutical Main Business

Table 160. Jiangsu Hansoh Pharmaceutical Latest Developments

Table 161. Novo Nordisk Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors

Table 162. Novo Nordisk Non-Insulin Hypoglycemic Drug Product Offered

Table 163. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

- Table 164. Novo Nordisk Main Business
- Table 165. Novo Nordisk Latest Developments
- Table 166. Emisphere Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 167. Emisphere Non-Insulin Hypoglycemic Drug Product Offered
- Table 168. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 169. Emisphere Main Business
- Table 170. Emisphere Latest Developments
- Table 171. Uni-Bio Science Group Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 172. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Offered
- Table 173. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 174. Uni-Bio Science Group Main Business
- Table 175. Uni-Bio Science Group Latest Developments
- Table 176. Takeda Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 177. Takeda Non-Insulin Hypoglycemic Drug Product Offered
- Table 178. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 179. Takeda Main Business
- Table 180. Takeda Latest Developments
- Table 181. 3SBio Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 182. 3SBio Non-Insulin Hypoglycemic Drug Product Offered
- Table 183. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 184. 3SBio Main Business
- Table 185. 3SBio Latest Developments
- Table 186. Jiangsu Hengrui Medicine Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
- Table 187. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Offered
- Table 188. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 189. Jiangsu Hengrui Medicine Main Business
- Table 190. Jiangsu Hengrui Medicine Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Non-Insulin Hypoglycemic Drug
- Figure 2. Non-Insulin Hypoglycemic Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Non-Insulin Hypoglycemic Drug Sales Growth Rate 2017-2028 (K Units)
- Figure 7. Global Non-Insulin Hypoglycemic Drug Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. Non-Insulin Hypoglycemic Drug Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Sulfonylureas
- Figure 10. Product Picture of Meglitinides
- Figure 11. Product Picture of Biguanides
- Figure 12. Product Picture of Thiazolidinediones
- Figure 13. Product Picture of Alpha Glucosidase Inhibitors
- Figure 14. Product Picture of Others
- Figure 15. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type in 2021
- Figure 16. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2017-2022)
- Figure 17. Non-Insulin Hypoglycemic Drug Consumed in Hospital Pharmacies
- Figure 18. Global Non-Insulin Hypoglycemic Drug Market: Hospital Pharmacies (2017-2022) & (K Units)
- Figure 19. Non-Insulin Hypoglycemic Drug Consumed in Retail Pharmacies
- Figure 20. Global Non-Insulin Hypoglycemic Drug Market: Retail Pharmacies (2017-2022) & (K Units)
- Figure 21. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
- Figure 22. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application in 2021
- Figure 23. Non-Insulin Hypoglycemic Drug Revenue Market by Company in 2021 (\$ Million)
- Figure 24. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company in 2021
- Figure 25. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Geographic Region (2017-2022)

- Figure 26. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Geographic Region in 2021
- Figure 27. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2017-2022)
- Figure 28. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Country/Region in 2021
- Figure 29. Americas Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
- Figure 30. Americas Non-Insulin Hypoglycemic Drug Revenue 2017-2022 (\$ Millions)
- Figure 31. APAC Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
- Figure 32. APAC Non-Insulin Hypoglycemic Drug Revenue 2017-2022 (\$ Millions)
- Figure 33. Europe Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
- Figure 34. Europe Non-Insulin Hypoglycemic Drug Revenue 2017-2022 (\$ Millions)
- Figure 35. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
- Figure 36. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue 2017-2022 (\$ Millions)
- Figure 37. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Country in 2021
- Figure 38. Americas Non-Insulin Hypoglycemic Drug Revenue Market Share by Country in 2021
- Figure 39. United States Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)
- Figure 40. Canada Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)
- Figure 41. Mexico Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)
- Figure 42. Brazil Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)
- Figure 43. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Region in 2021
- Figure 44. APAC Non-Insulin Hypoglycemic Drug Revenue Market Share by Regions in 2021
- Figure 45. China Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)
- Figure 46. Japan Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)
- Figure 47. South Korea Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)
- Figure 48. Southeast Asia Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022

(\$ Millions)

Figure 49. India Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 50. Australia Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 51. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country in 2021

Figure 52. Europe Non-Insulin Hypoglycemic Drug Revenue Market Share by Country in 2021

Figure 53. Germany Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 54. France Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 55. UK Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 56. Italy Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 57. Russia Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 58. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country in 2021

Figure 59. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Market Share by Country in 2021

Figure 60. Egypt Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 61. South Africa Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 62. Israel Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 63. Turkey Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 64. GCC Country Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 (\$ Millions)

Figure 65. Manufacturing Cost Structure Analysis of Non-Insulin Hypoglycemic Drug in 2021

Figure 66. Manufacturing Process Analysis of Non-Insulin Hypoglycemic Drug

Figure 67. Industry Chain Structure of Non-Insulin Hypoglycemic Drug

Figure 68. Channels of Distribution

Figure 69. Distributors Profiles

I would like to order

Product name: Global Non-Insulin Hypoglycemic Drug Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/G765EC5711ABEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G765EC5711ABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970